Extended Data Fig. 8: Correlation analysis between tissue LIF levels and clinical parameters of PDAC.
From: Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring
a–c, ELISA of LIF levels (a), and immunoblot and immunohistochemistry analyses of STAT3 activation in mouse pancreatic tissues at various stages of PDAC pathogenesis. Scale bars: black, 200 µm; blue, 50 µm. d, Mouse serum LIF levels at various stages of pancreas pathogenesis analysed by ELISA. e, Summary table of clinical parameters of the human cases from whom pancreatic tissue samples were collected for ELISA assays and correlation analysis. f, Correlation analysis of human tissue LIF levels and indicated clinical parameters by χ2-analysis. g, Correlation analysis between tissue LIF mRNA levels and disease-free survival of patients with stage I or IIa PDAC at diagnosis by Mantel–Cox log-rank test and presented as a Kaplan–Meier survival curve. Data derived from the TCGA database. h, Correlation analysis between the changes in circulating LIF or CA19-9 levels and tumour status scored by RECIST grade during multi-cycle therapeutic treatment by ROC analysis. n = 51 data points. i, Serum LIF levels in patients with various solid cancers by Simoa ELISA. j, Graphic summary of LIF action in pancreatic carcinogenesis.
